Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: Is tumor budding the missing link?

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Karamitopoulou, Eva ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biomarker; Epithelial mesenchymal transition; Pancreatic cancer; Prognosis; Tumor budding

Indexed keywords

BETA CATENIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ 5 GAMMA 2; MEMBRANE PROTEIN; MICRORNA 10B; MICRORNA 141; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; NOTCH2 RECEPTOR; OXALIPLATIN; PACLITAXEL; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; METASTASIS; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR BUDDING; TUMOR GROWTH; TUMOR INVASION; UPREGULATION;

EID: 84891107628     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00221     Document Type: Short Survey

References (51)

1. Hidalgo M. Pancreatic cancer. N Engl J Med (2010) 362:1605-17. doi:10.1056/NEJMra0901557
2. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol (2005) 70:65-72. doi:10.1101/sqb.2005.70.040
3. Fernandez-del-Castillo C, Jimenez RE, Steer ML. Surgery in the treatment of exocrine pancreas and prognosis. In: Tanabe KK, editor (2013). Available from: www.uptodate.com
4. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett (2012). Available from: http://dx.doi.org/10.1016/j canlet.2012.03.018
5. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med (2007) 7:504-21. doi:10.2174/156652407781387082
6. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119:1420-8. doi:10.1172/JCI39104
7. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871-90. doi:10.1016/j.cell.2009.11.007
8. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 102:340-51. doi:10.1093/jnci/djp535
9. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2010) 101(2):293-9. doi:10.1111/j.1349-7006.2009.01419.x
10. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 119:1417-9. doi:10.1172/JCI39675
11. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2012) 173:105-12. doi:10.1016/j.jss.2011.09.020
12. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 172:973-81. doi:10.1083/jcb.200601018
13. Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res (2007) 13:4769-76. doi:10.1158/1078-0432.CCR-06-2926
14. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 69:5820-8. doi:10.1158/0008-5472.CAN-08-2819
15. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther (2007) 6:532-41. doi:10.1158/1535-7163.MCT-06-0462
16. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett (2010) 295:214-28. doi:10.1016/j.canlet.2010.03.003
17. Prall F. Tumour budding in colorectal carcinoma. Histopathology (2007) 50:151-62. doi:10.1111/j.1365-2559.2006.02551.x
18. Brown M, Sillah K, Griffiths EA, Swindell R, West CM, Page RD, et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology (2010) 56:893-9. doi:10.1111/j.1365-2559.2010.03559.x
19. Koike M, Kodera Y, Itoh Y, Nakayama G, Fujiwara M, Hamajima N, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol (2008) 15:1977-82. doi:10.1245/s10434-008-9901-6
20. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer (2009) 115:3324-34. doi:10.1002/cncr.24390
21. Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus (2004) 17:333-7. doi:10.1111/j.1442-2050.2004.00436.x
22. Ohike N, Coban I, Kim GE, Basturk O, Tajiri T, Krasinskas A, et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol (2010) 34:1417-24. doi:10.1097/PAS.0b013e3181f0b05a
23. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1:651-61.
24. Muto T, Mochizuki H, Masaki T editors. Tumor Budding in Colorectal Cancer: Recent Progress in Colorectal Cancer Research (Horizons in Cancer Research). (Vol. 8). Tokyo: Nova (2006).
25. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 28:151-66. doi:10.1007/s10555-008-9179-y
26. Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2013) 26:295-301. doi:10.1038/modpathol.2012.155
27. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology (2005) 52: 1432-5.
28. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg (2004) 91:327-33. doi:10.1002/bjs.4429
29. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology (2002) 40:127-32. doi:10.1046/j.1365-2559.2002.01324.x
30. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol (2009) 33:134-41. doi:10.1097/PAS.0b013e318184cd55
31. Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Patsouris E, Gennatas K, et al. Tumor budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer (2013) 49:1032-9. doi:10.1016/j.ejca.2012.10.022
32. Calin GA, Croce CM. Micro RNA signatures in human cancers. Nat Rev Cancer (2006) 6:857-66. doi:10.1038/nrc1997
33. McShane L, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Eur J Cancer (2005) 41:1690-6. doi:10.1016/j.ejca.2005.03.032
34. Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Gen Dev (2005) 15:200-5. doi:10.1016/j.gde.2005.01.002
35. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 8:843-52. doi:10.4161/cc.8.6.7907
36. Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, et al. MicroRNA10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 17:5812-21. doi:10.1158/1078-0432.CCR-11-0695
37. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 10:593-601. doi:10.1038/ncb1722
38. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 9:582-9. doi:10.1038/embor.2008.74
39. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 11:1487-95. doi:10.1038/ncb1998
40. Panarelli NC, Chen YT, Zhou XK, Kitabayashi N, Yantiss RK. MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas (2012) 41:685-90. doi:10.1097/MPA.0b013e318243a905
41. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 12:2171-6. doi:10.1007/s11605-008-0584-x
42. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 9:169. doi:10.1186/1476-4598-9-169
43. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res (2007) 67:1030-7. doi:10.1158/0008-5472.CAN-06-2030
44. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol (2008) 26:2806-12. doi:10.1200/JCO
45. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer (2009) 125:2323-31. doi:10.1002/ijc.24573
46. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 1:313-23. doi:10.1016/j.stem.2007.06.002
47. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 69:6704-12. doi:10.1158/0008-5472.CAN-09-1298
48. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 12:4147-53. doi:10.1158/1078-0432.CCR-06-0038
49. Shah AN, Summy JM, Zhang J, Park S, Parikh N, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 14:3629-37. doi:10.1245/s10434-007-9583-5
50. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 138:592-603. doi:10.1016/j.cell.2009.07.011
51. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol (2005) 23:1228-36. doi:10.1200/JCO.2005.06.050